Wall Street analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) to post earnings per share (EPS) of ($0.89) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Trillium Therapeutics’ earnings. The lowest EPS estimate is ($1.19) and the highest is ($0.59). Trillium Therapeutics reported earnings per share of ($0.86) during the same quarter last year, which would suggest a negative year over year growth rate of 3.5%. The company is scheduled to announce its next quarterly earnings results on Friday, March 9th.
According to Zacks, analysts expect that Trillium Therapeutics will report full-year earnings of ($3.71) per share for the current fiscal year, with EPS estimates ranging from ($4.76) to ($1.98). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.70) per share, with EPS estimates ranging from ($3.56) to ($1.62). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Trillium Therapeutics.
Several research firms have recently weighed in on TRIL. Zacks Investment Research raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Trillium Therapeutics in a research report on Thursday, December 14th. Finally, ValuEngine downgraded shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Trillium Therapeutics presently has an average rating of “Buy” and an average target price of $13.33.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at $7.45 on Friday. The firm has a market cap of $83.88, a PE ratio of -1.97 and a beta of 1.80. Trillium Therapeutics has a 1 year low of $4.15 and a 1 year high of $13.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.